Eukaryotic transcription is governed, in part, by DNAbinding transcription factors (TFs), which assemble at promoter and enhancer sequences throughout the genome. A characteristic feature of promoters and enhancers is the presence of sequence motifs that allow multiple TFs to bind across the same region. In addition to sequence-specific DNA-binding domains, TFs typically have separate activation domains that interact with transcription regulators. The Mediator complex, which is comprised of 26 subunits in mammals (and up to 21 subunits in yeast; BOX 1), is a general target of TF activation domains; moreover, as different TFs bind to different Mediator subunits, multiple TFs might bind to Mediator at the same time.
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. The large size of Mediator is likely to facilitate these diverse functional interactions.
Indicative of its functional versatility, Mediator is implicated in regulating at least some aspect of many fundamental processes involved in transcription, including transcription initiation, transcription elongation, chromatin architecture and enhancer-promoter gene looping.
Throughout this Review, we emphasize the role of Mediator in some of these processes and direct readers to other recent reviews that address additional aspects of Mediator structure and function 2, 3 , or the roles of Mediator in selected human diseases [4] [5] [6] .
Mediator composition and structure A fundamentally important characteristic of Mediator is that its subunit composition can change; subunits can be lost or added to affect its biological function. Little is known about how subunit exchange is regulated, and this remains an area of great interest and importance. Mass spectrometry analyses have indicated that although most Mediator subunits are present in similar numbers in human and yeast cells, select subunits are markedly overor under-represented 7 . Furthermore, several laboratories have isolated mammalian Mediator complexes lacking one or more of the 26 core Mediator subunits 8, 9 . These results suggest that a subset of endogenous Mediator complexes may lack specific subunits. Mediator complexes that lack specific subunits cannot transduce activation signals from TFs that would usually bind to the missing subunits. For example, the thyroid hormone receptor binds to the MED1 sub unit and the ELK1 TF binds to the MED23 subunit 10, 11 . In MED1-knockout murine embryonic fibroblasts (MEFs), the activation of thyroid hormone receptor target genes was inhibited 12 ; similarly, ELK1 was unable to activate its target genes in MED23-knockout murine embryonic stem cells 11 . Importantly, however, Mediator complexes lacking MED1 or MED23 can activate transcription in response to TFs that bind to other Mediator subunits 
Enhancer-promoter gene looping
Looping of genomic DNA that juxtaposes an enhancer, which may be dozens (or more) of kilobases away, and a promoter.
. The molecular mechanisms underlying the reversible CDK8 module-Mediator association are incompletely understood, but recent studies indicate that the phosphorylation, ubiquitylation and protein turnover of MED13 are involved 20 . The targeted degradation of MED13 is expected to affect the association of the CDK8 module with Mediator, as MED13 directly links the CDK8 modul e to Mediator in both yeast and humans 18, 19 . Subunits of the CDK8 module have been implicated in a growing number of cancers and developmental diseases [21] [22] [23] [24] 
. Although some mechanistic details have been delineated 25, 26 , much remains to be discovered regarding the altered function of CDK8 module subunits with pathogenic mutations. The general lack of understanding stems from insufficient structural data and the fact that connections between CDK8 module subunits and human diseases have been made fairly recently. In addition, CDK8 seems to function in context-specific ways; its biological function may vary among different cell types or in response to distinct stimuli. For example, in HCT116 cells, CDK8 regulates different genes during hypoxia or in response to serum 27, 28 . As a kinase that reversibly associates with Mediator, CDK8 seems to be poised to broadly regulate gene expression. Although few CDK8 kinase targets have been identified, DNA-binding TFs represent common targets in yeast and human cells, suggesting that CDK8 may serve as a general regulator of TF function. Phosphorylation by yeast or human CDK8 seems to regulate TF activity and/or target TFs for proteasomal degradation 29, 30 . As examples, Cdk8-dependent phosphorylation of Gal4 or Sip4 activates these yeast TFs 31, 32 , whereas CDK8-dependent phosphorylation of the human TFs sterol regulatory element-binding protein 1c or E2F1 seems to repress their activity 33, 34 . Another important consideration is the presence of CDK19, MED12L and MED13L -paralogues of CDK8, MED12 and MED13, respectively, that have emerged in vertebrate organisms. Little is known about the biological roles of these paralogues, but they appear to assemble in a mutually exclusive manner 35 . Specifically, mass spectrometry analyses have revealed that MED12 and MED12L will not associate in the same kinase module, nor will MED13 and MED13L or CDK8 and CDK19. CDK19, MED12L and MED13L have been linked to neuronal and developmental disorders 36, 37 , but their basic biological importance relative to CDK8, MED12 or MED13 remains unclear.
Structural dynamics of Mediator. Mediator is dynamic not only in its subunit composition but also in its structure. An abundance of computationally predicted intrinsicall y disordered regions (IDRs) are observed in both yeast and human Mediator subunit sequences 38 , and a high degree of structural flexibility is evident based on electron microscopy analyses of Mediator 17, 39, 40 . In addition, the structural state of Mediator can shift dramatically upon binding to other proteins or protein complexes (FIG. 1) . In each case, structural shifts in Mediator correlate with changes in Mediator function. Structural shifts that occur upon TF-Mediator binding (FIG. 1a) , which seem to propagate throughout the entire Mediator complex 17 , correlate with the activation of Pol II transcription 41 . Large-scale structural shifts also occur upon the binding of Mediator to Pol II (FIG. 1b) or the CDK8 module (FIG. 1c) ; these structural changes may ensure that the binding of Pol II and the CDK8 module to Mediator is mutually exclusive. Numerous structural, functional and biochemical assays have
Box 1 | The evolution of Mediator
Consistent with its role as a general transcription factor (TF) 175 , the emergence of Mediator in eukaryotes coincided with the emergence of other general TFs, such as TFIIH and the TATA-binding protein-associated factor (TAF) subunits of TFIID. However, throughout eukaryotic evolution, the subunit composition, sequences 176 and function of Mediator diversified 2 . The poor sequence conservation between yeast and human Mediator (see Supplementary information S1 (table)) may partly reflect the high proportion of predicted intrinsically disordered regions (IDRs) within its subunit sequences 38 , which generally tend to diverge more rapidly over time 177 . As a general target of DNA-binding TFs, the divergence of Mediator sequences throughout evolution may have been partially driven by the increasing diversity of DNA-binding TFs. An intriguing hypothesis is that Mediator may have evolved as a type of cellular defence mechanism against 'selfish' DNA elements from viruses and transposons 178 . The transcription of these DNA elements is deleterious to the host, and Mediator may help to ensure that transcription activation uses host-specific factors, such as endogenous TFs and co-activators. This could be one basis for Mediator's ancient origins in eukaryotes 176 . Many basic functions of Mediator are conserved from yeast to humans -for example, the ability of Mediator to bind to TFs and the carboxy-terminal domain (CTD) of RNA polymerase II (Pol II), and its requirement for Pol II transcription genome-widebut Mediator also regulates and interacts with various chromatin-or Pol II-associated factors that are not present in yeast genomes, such as POLR2M 72, 75 , negative elongation factor (NELF) 179 and activator RNAs
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. Mediator also seems to be essential for long-range enhancer-promoter interactions in mammalian cells 102, 128 , whereas similar enhancer-dependent regulatory mechanisms are not observed in yeast 122 .
Uterine leiomyomas
Benign tumours of smooth muscle cells originating from the uterus.
Head module
The yeast Mediator subunits Med6, Med8, Med11, Med17, Med18, Med19, Med20 and Med22.
Middle module
The yeast Mediator subunits Med1, Med4, Med7, Med9, Med10, Med21 and Med31.
Tail module
The yeast Mediator subunits Med2, Med3, Med5, Med14, Med15 and Med16.
Crystal structure docking
Fitting an existing crystal structure into a larger structural model. demonstrated that Pol II-Mediator binding precludes the association of the CDK8 module with Mediator and, conversely, that the CDK8-Mediator complex does not associate with Pol II. For instance, Mediator complexes bound to the Pol II carboxy-terminal domain (CTD) lack any detectable CDK8 module subunits 42 , and proteomic data for CDK8-Mediator yield no detectable co-purifyin g Pol II sub units 43 . As existing structural data for the large assemblies depicted in FIG. 1 are of low resolution, the precise nature of the structural shifts they undergo remains unknown. It is not clear how many subunits are involved in a given TF-Mediator structural shift or which subunit-subunit interfaces are changed. TF-induced structural changes appear to be a conserved feature of Mediator 44 , and the general conservation of IDRs 38 and conformational flexibility from yeast to humans suggests that structural plasticity is a fundamental aspect of Mediator's cellular functions.
Indicative of its structural complexity, recent electron microscopy studies have completely redefined previous architectural models of yeast Mediator, which had assigned subunits to the so-called head module, middl e module and tail module sections of the complex. A key feature of the more recent studies was the implementation of electron microscopy labelling strategies to identify the location of select subunits for the first time. The resulting models, aided by crystal structure docking of individual Mediator subunits, allowed a more accurate delineation of the head, middle and tail modules 44, 45 . Whereas previous structural models placed tail domain subunits away from a Pol II-Mediator binding site 46 , the new models position the tail subunits adjacent to this site. These results clarify some confounding issues with the previous models, including how tail module sub units could influence Pol II-Mediator interactions 47 and the assembly of the pre-initiation complex (PIC) [48] [49] [50] [51] 
, and how the interaction of the CDK8 module with head module subunits was observed in yeast two-hybrid screens 52 . The question of whether the subunit organization of mammalian Mediator complexes is similar to that of yeast is complicated by the fact that humans have additional Mediator subunits (see Supplementary information S1 (table) ). However, a partial human Mediator complex (15 subunits) was recently reconstituted, and this has provided the most information to date about this basic query 53 . Crosslinking-mass spectrometry studies of this 15-subunit Mediator complex showed similarities and differences between yeast and human Mediator in terms of overall subunit organization 53 . As existing subunit-subunit interaction data for yeast and human Mediator (for example, via crystal structures or crosslinking-mass spectrometry) have, understandably, involved partial assemblies [53] [54] [55] [56] [57] , it remains to be determined whether potential differences in subunit organization will persist upon the comparison of fully assembled complexes. These questions should be answered in the next few years.
Mediator in Pol II transcription
Mediator is generally required for PIC assembly
, as revealed by a host of biochemical, cellular and genetic studies in human cells and model organisms. In agreement with this finding, structural studies showed that Mediator makes extensive contacts with Pol II 39, 58, 59 , which serves as a central scaffold around which the rest of the PIC assembles. Mediator is also a general target for DNA-binding TFs, invoking a 'molecular bridge' model in which Mediator integrates and communicates regulatory signals from DNA-binding TFs directly to the Pol II enzyme and the rest of the PIC. This central and funda mental role for Mediator is consistent with its global requirement for Pol II transcription 60, 61 . PIC assembly. For gene-specific transcription (that is, regulated transcription), Pol II must be recruited to specific sites on the genome. This is generally controlled by sequence-specific, DNA-binding TFs. Although TFs do not directly bind to Pol II, one mechanism by which they can promote Pol II recruitment is by binding to the Mediator complex. Mediator enables Pol II recruitment via interaction with the CTD of the Pol II RPB1 sub unit 42, [62] [63] [64] . The large size of Mediator is likely to promote stable PIC formation by allowing the complex to directly interact with multiple PIC factors (FIG. 2a) . Numerous laboratories have shown cooperative and even synergistic functions between Mediator and TFIID during PIC assembly and transcription activation [65] [66] [67] [68] [69] ; more over, Mediator helps to regulate the recruitment and/ or the activity of the PIC components TFIIA, TFIIB, TFIIE and TFIIF within promoter-bound PICs [70] [71] [72] .
Box 2 | Mediator and human disease
The number of diseases identified as linked to Mediator subunits or Mediator subunit mutations is increasing, including a growing number of links to developmental diseases and cancer 4, 5, 180 . This information is medically important, but it can also help to delineate cellular functions for specific subunits. For example, mutations in the gene encoding MED12 found in uterine leiomyomas were shown to affect its interaction with the cyclin-dependent kinase 8 (CDK8) module subunit CCNC, which negatively affected the kinase function of CDK8 (REF. 26 ).
The biological and structural characteristics of Mediator suggest that it could represent an effective therapeutic target 181 . As different transcription factors (TFs) bind to different Mediator subunits, blocking one TF-Mediator interaction site (for example, the site at which VP16 interacts with MED25) may not broadly inhibit cellular transcription. This is supported by the fact that knockout of single Mediator subunits can shut down transcriptional responses to specific signalling pathways while leaving other pathways intact 11, 12, 154 . Moreover, in the few cases in which structural data are available, the TF binding site within a Mediator subunit is structured, with hydrophobic clefts or patches that could be selectively targeted with small molecules [182] [183] [184] . Genome-wide chromatin immunoprecipitation followed by sequencing (ChIP-seq) analyses in mammalian cells have uncovered enhancer elements that are unusually large and that have high-level occupancy of DNA-binding TFs and other transcription regulators such as cohesin and Mediator. These domains have been called superenhancers 185, 186 , and they seem to be similar to high-occupancy target (HOT) domains 187, 188 or locus control regions (LCRs) 189 that have been identified in other studies. Super-enhancers are essentially clusters of enhancers, and they typically regulate the expression of genes that control cell identity; super-enhancers can also drive high expression levels of oncogenes in cancer cells. Mediator seems to have a key role in forming or maintaining super-enhancer structure and function 185 ; in fact, perturbing Mediator structure by knocking down key subunits, such as MED12, disproportionately affects genes regulated by super-enhancers 102, 186 , suggesting that targeting Mediator may selectively disrupt oncogene expression in cancer.
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CTD repeats
A series of YSPTSPS repeats within the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II.
Mediator also helps to recruit the multisubunit TFIIH complex to the PIC, most likely via an interaction with the MED11 sub unit of Mediator 73, 74 . An additional role for Mediator in PIC assembly seems to involve Pol II complexes that contain GDOWN1, which is now considered to be a thirteenth subunit of Pol II called POLR2M. POLR2M was identified as a factor that repressed transcription in the absence of Mediator in vitro 75 . Later work has shown that POLR2M affects PIC assembly by inhibiting TFIIF-Pol II binding 72, 76 . In fact, structural and biochemical data indicate that the binding of TFIIF and POLR2M to the free Pol II enzyme is mutually exclusive 72, 77 . However, in the presence of Mediator, it seems that TFIIF can associate with Pol II complexes containing POLR2M and this, in turn, may promote the formation of active PICs 72 . The central role of Mediator in regulating POLR2M and TFIIF-Pol II interactions may also have important implications in Pol II pausing and elongation 76 (see below).
Pol II initiation. Following PIC assembly and the formation of the open complex, Pol II must break contacts with Mediator and the PIC to leave the promoter and transition to productive elongation. Although many mechanistic details remain to be discovered, phosphorylation of the CTD of Pol II plays a key part in disrupting the Mediator-Pol II interaction 78 (FIG. 2a) . In particular, the Pol II CTD is phosphorylated by TFIIH (via its CDK7 kinase subunit), and this is accompanied by Pol II (and thus transcription) initiation 79, 80 . The ability of TFIIH to phosphorylate the Pol II CTD is dependent on Mediator 41, 62, 81, 82 , but it is unknown whether Mediator regulates other enzymatic functions within TFIIH. It also remains unknown how many CTD repeats must be phosphorylated to sufficiently disrupt MediatorPol II binding in order to enable Pol II to escape from the promoter. Recent results in yeast have shown that the TFIIH-dependent phosphorylation of the Pol II CTD contributes to, but is not required for, the disruption of Mediator-Pol II contacts at the promoter 83, 84 . Whereas promoter-proximal paused Pol II does not seem to be a common regulatory intermediate in yeast 85 , these and other 86 findings suggest a conserved role for Mediator in the regulation of the escape of Pol II from promoters.
Pol II pausing and Pol II elongation. In metazoans, the Pol II enzyme can pause after transcribing 30-60 nucleotides 87, 88 ; these 'paused' Pol II complexes are widely observed at promoter-proximal sites throughout the genome, which establishes paused Pol II complexes as common regulatory intermediates [89] [90] [91] . Although Mediator appears to regulate Pol II pausing and/or pause release, the molecular mechanisms remain unclear 41, [92] [93] [94] . For example, it is not known whether Mediator remains bound to paused Pol II or whether paused Pol II complexes dissociate from Mediator (FIG. 2b) ; if MediatorPol II contacts are broken during early initiation and pausing stages, the Mediator-dependent regulation of Pol II pausing or pause release would require Mediator to associate with intermediary factors. A growing set of proteins and protein complexes are known to regulate Pol II pausing or elongation in metazoans 95 . Among these, many physically or functionally interact with Mediator, including POLR2M and the super elongation complex (SEC).
Whereas Mediator has been shown to regulate PIC assembly in the presence of POLR2M (see above), biochemical, gene expression and chromatin immunoprecipitation followed by sequencing (ChIP-seq) data have also implicated Mediator in regulating the potential functions of POLR2M in Pol II pausing and/or elongation 72, 76 . In vitro transcription assays indicate that POLR2M stabilizes Pol II pausing, at least in part, through blocking pause termination by transcription termination factor 2 (TTF2) 76 . Furthermore, POLR2M colocalized with paused Pol II across the genome, and POLR2M knockdown caused an increase in Pol II density downstream of pause sites 76 . As Mediator seems to be essential for activating PICs that contain POLR2M 72, 75 , these data suggest additional roles for Mediator in the regulation of Pol II pausing and elongation. As the structure of Mediator changes, its ability to interact with other regulatory proteins may also change. Such structural transitions could enable the same Mediator complex to adopt distinct functions at the appropriate stages of transcription (for example, during initiation as opposed to elongation). The model also allows some cofactors to bind to Mediator in more than one structural state. a | Upon binding a transcription factor (TF), Mediator undergoes structural changes that facilitate interactions with additional transcription regulators 43 . Structural changes associated with TF-Mediator binding also seem to promote the stable association of this complex with RNA polymerase II (Pol II) 197 and correlate with transcription activation 41 . b | Pol II-Mediator binding triggers distinct structural changes throughout Mediator 58, 59 ; these might be important for functional interactions between Mediator and factors that promote Pol II initiation and/or elongation (depicted as generic cofactors), such as TFIIS, TFIIF or POLR2M 72, 76, 104, 105 . c | Cyclin-dependent kinase 8 (CDK8) module-Mediator binding also induces structural changes in Mediator that prevent Pol II binding 18, 198 ; furthermore, CDK8-Mediator associates with elongation factors (depicted as generic cofactors), such as the super elongation complex (SEC) 27, 43 , which may regulate the timing of SEC recruitment at some genes. , appears to be a general regulator of Pol II elongation and contains factors such as positive transcription elongation factor-b (P-TEFb), AF4/FMR2 family member 4 (AFF4) and eleven-nineteen Lys-rich leukaemia (ELL). The metazoan-specific MED26 subunit of Mediator interacts with the SEC to facilitate Pol II elongation at a subset of genes 68 . Interestingly, a region on MED26 to which the SEC binds was also shown to bind to TFIID, suggesting that MED26 acts as a switch, perhaps initially binding to TFIID to promote PIC assembly and then, in response to an activating signal, binding to the SEC to control elongation 68 . Another mechanistic link has been observed between the SEC and CDK8-Mediator complexes (FIG. 2b) . SEC subunits, including CDK9, cycli n T1 (CCNT1) and AFF4, interact with CDK8-Mediator complexes 43 , and knockdown of CDK8 negatively affects transcription elongation and the recruitment of SEC factors at gene promoters activated during serum response 27 . Similarly, Pol II elongation and the recruitment of SEC at hypoxia-inducible genes are highly sensitive to CDK8 protein levels 28 . These findings suggest that CDK8-Mediator stimulates Pol II elongation. As the association of the CDK8 module with Mediator is mutually exclusive with Pol II, CDK8-Mediatorcontrolled regulation of Pol II elongation is likely to occur after Pol II-Mediator interactions are disrupted. Under these circumstances, the SEC may function as an intermediary factor (FIG. 2b) . Interestingly, MED26 and the CDK8 module are rarely in the same Mediator complex 43, 98 , and it will be interesting to determine whether MED26 and CDK8-Mediator regulate the occupancy or activity of the SEC across the genome. Their varied association with Mediator suggests that MED26 and CDK8-Mediator regulate SEC function in mechanistically distinct ways.
Interestingly, the functional cooperativity between Mediator and POLR2M or the SEC has been proposed to involve a structural remodelling or switching mechanism 68, 76 . Consistent with this, structural shifts in Mediator are induced by TF-Mediator binding. TF-Mediator binding triggers structural changes at the Pol II-Mediator interaction site, which correlate with activation of Pol II at the promoter 2 . In agreement with this finding, numerous laboratories have documented that the Mediator-dependent activation of Pol II elongation coincides with the binding of TFs, such as heat shock factor protein 1 (HSF1), ELK1 or p53, to promoters 41, 99, 100 . Much remains to be discovered regarding the mechanisms by which Mediator contributes to the regulation of Pol II pausing and elongation. In addition to POLR2M and the SEC, other factors involved in regulating Pol II pausing and elongation have been shown to have mechanistic links to Mediator, including cohesin 101, 102 , ELL3 (REF. 103 ), TFIIS [104] [105] [106] and DRB-sensitivity-inducing factor (DSIF) 107 . This elaborate and expanding network of factors, the regulatory roles of which are still emerging, coupled with the dynamic and apparently combinatorial nature of the Pol II initiation and elongation machinery, suggests that delineation of specific mechanistic details will require structural, cellular and biochemica l assays, including studies with reconstituted in vitro transcriptio n systems.
Pol II re-initiation. After Pol II transcription initiation and promoter escape, another Pol II enzyme could bind to the promoter and initiate another transcript (FIG. 2c) . This process, called re-initiation, can generate multiple transcripts via the recruitment of additional Pol II enzymes. As a sustained transcriptional response is likely to require efficient re-initiation, this is probably a key regulatory stage at active genes 108 . In vitro experiments have demonstrated that transcription re-initiation occurs more rapidly than the initial round of transcription 109 and that it is facilitated by scaffold PIC assemblies
Box 3 | The pre-initiation complex
The eukaryotic RNA polymerase II (Pol II) enzyme transcribes most non-coding RNA genes and all protein-coding genes. Unlike bacterial polymerases, however, Pol II relies on an array of auxiliary factors that ensure transcription initiation occurs at the correct site in the genome, and that ensure that RNA processing events result in the production of a mature transcript 190 . At the transcription start site, Pol II initiation is regulated by a protein assembly known as the pre-initiation complex (PIC) 191 (see the figure) . Each of the factors that constitute the PIC (transcription factor IIA (TFIIA), TFIIB, TFIID, TFIIE, TFIIF, TFIIH, Pol II and Mediator) have varied functional and structural roles 192 , but much remains unknown about how the PIC functions as a unit. Biophysical studies have begun to determine the overall structure and architecture of the PIC. Although current results suggest different architectures for human and yeast PICs 193, 194 , this remains an area of active investigation 195 . Finally, even though the PIC can function in various forms (for example, the PIC contains simpler TFIID assemblies in differentiated cells), it represents a fundamental intermediate in transcription initiation that is targeted by an array of general and gene-specific regulatory factors. The asterisk (see the figure) indicates that TFIID contains a TATA-binding protein (TBP) and 13 different TBP-associated factors (TAFs), 5 of which dimerize (TAF4, TAF5, TAF6, TAF9 and TAF12) 196 . that remain following Pol II promoter escape 110 . These scaffold assemblies appear to be stabilized by DNAbinding TFs and retain most PIC factors, including Mediator, but lack Pol II and TFIIF (FIG. 2c) .
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Although TF turnover via proteasome-mediated degradation represents one simple means to regulate transcription re-initiation (that is, additional TFs must then be physically present to replace degraded TFs) 111 , the CDK8 module alone, and as part of the CDK8-Mediator complex, may also have an important role 18 . ChIP-seq data suggest that the CDK8 module colocalizes with Mediator across the genome 28, 102 ; however, sequential chromatin immunoprecipitation (ChIP-reChIP) and biochemical assays indicate that the association of the CDK8 module with Mediator is transient and reversible 18, 112 . In stark contrast to the core Mediator complex, CDK8-Mediator does not interact with Pol II or the Pol II CTD 42, 43 ; thus, CDK8 module-Mediator binding will prevent Pol II from being incorporated into the PIC 18, 113 . In addition, the occupancy of CDK8 and TFIIH seems to be mutually exclusive at the HIV-1 promoter, suggesting that CDK8-Mediator disrupts Mediator-TFIIH interactions as well 114 . Following transcription initiation and Pol II promoter escape, binding of the CDK8 module to Mediator would prevent a second Pol II enzyme from immediately re-engaging the promoter (FIG. 2b) . Disruption of CDK8 module-Mediator interactions would then be required to enable the PIC to fully re-assemble for the re-initiation of transcription (FIG. 2c) .
As the CDK8 module can negatively regulate Mediator-Pol II interactions, it is fundamentally important to understand how CDK8 module-Mediator binding is regulated. PARP1, which catalyses the poly(ADP) ribosylation of proteins, and the FBW7 ubiquitin ligase have been shown to regulate the CDK8 moduleMediator interaction in human cells 20, 115 . PARP1 promotes the release of the CDK8 module from Mediator independently of its catalytic activity 115 . By contrast, ubiquitylation of MED13 by FBW7 (which required FBW7 to bind to a metazoan-specific phospho-degron motif in MED13) promoted the proteasome-mediated degradation of MED13 (REF. 20 ). As MED13 directly links the CDK8 module to Mediator 18, 19 , inhibition of MED13 degradation resulted in an increased level of CDK8-Mediator in cells 20 .
Mediator and chromatin architecture
In eukaryotes, genomic DNA is wrapped around histone proteins, and this 'packaged' genomic DNA is called chromatin. Chromatin provides a general barrier to gene expression; compared with unobstructed 'naked' DNA, histone-bound DNA (that is, nucleosomal DNA) can block PIC assembly to suppress transcription. Mediator may simply maintain nucleosome-free regions at key regulatory loci, as demonstrated recently in yeast, in which the occupancy of Mediator at promoters correlated with PIC assembly, which seemed to block nucleosome assembly 116 . This model is analogous to results in Drosophila melanogaster, in which paused promoterproximal Pol II complexes helped to maintain nucleosome-free regions to promote transcription activation 117 .
Mediator also interacts with the SWI/SNF and CHD1 chromatin remodelling complexes [118] [119] [120] and appears to contribute to nucleosome displacement during transcriptio n activation in both yeast and humans 92, 106 . DNA looping. In all domains of life, the 3D organization of the genome has basic roles in coordinating gene expression programmes 121 . A common theme is the formation of loops that enable interaction between linearly separated DNA sequences. The architectural constraints and topological complexity appear to have increased substantially from bacteria to yeast and from yeast to mammals 122 . A general trend towards increasingly larger loops in more-complex organisms (that is, loops with a greater number of DNA bases spanning the interacting . At this stage, the Pol II carboxy-terminal domain (CTD) is not highly phosphorylated, but transcription factor IIH (TFIIH) phosphorylates it during transcription initiation 80 , after which the Pol II enzyme 'escapes' the promoter and begins to transcribe the gene. At some genes, Pol II may pause after transcribing ~60 nucleotides 95 ; whether this 'paused Pol II' remains associated with Mediator is unknown. b | The cyclin-dependent kinase 8 (CDK8) module may associate with Mediator after Pol II-Mediator contacts are broken, and this may regulate Pol II elongation or release from a paused state at some genes. CDK8-Mediator may regulate the recruitment or activity of the super elongation complex (SEC, which contains CDK9) to promote Pol II pause release and elongation 27, 28 . c | As CDK8-Mediator cannot interact with Pol II, re-initiation of transcription requires release of the CDK8 module. A scaffold PIC complex, which may be stabilized by a transcription factor, could facilitate rapid re-initiation 110 . Dashed arrows indicate enzymatic activity. sequences) has been observed, including interactions among sequence elements on different chromosomes in mammalian cells. Gene loops may represent a predominant regulatory mechanism in metazoans 1, 123 , and 3D chromatin organization may functionally replace operons to facilitate the coordinated regulation of sets of genes that are not adjacent along a chromosome 124 . Although Mediator is not required for the formation of gene loops per se -looping can be mediated by lacR in bacteria, which lack a recognizable Mediator complex -it has a central role in the formation and/ or stabilization of looped DNA structures in eukaryotes (FIG. 3) . In mammalian cells, long-range looping interactions between enhancer and promoter sequences appear to be important for driving high-level and cell type-specifi c gene expression [125] [126] [127] . Precisely how these loops are formed and stabilized remains uncertain, but Mediator, in conjunction with other factors, seems to have important roles 102, [128] [129] [130] . Whereas yeast genes are not regulated via long-distance enhancer-promoter interactions 122 , it is notable that mutant forms of Sin4 (the yeast orthologue of Med16) were identified in Saccharomyces cerevisia e that enabled upstream activating sequences to activate transcription at longer distances from the promoter than normally observed in yeast (upstream activating sequences are normally only 100-200 base pairs from the promoter TATA sequence) 131 . Furthermore, Mediator has been implicated in the formation of looped DNA structures between the 5ʹ and 3ʹ ends of yeast genes 132 . These findings suggest an ancient origin for Mediator in long-range interactions with Pol II.
Non-coding RNAs (ncRNAs) are key regulators of gene expression patterns and have important roles throughout human development. Mediator's large size and extensive surface area may allow it to interact with a diverse set of ncRNAs. In fact, some of the biological functions of ncRNAs overlap with known functions of the Mediator complex, such as their association with enhancer regions and their ability to regulate chromatin architecture. Recent studies suggest that these shared functions may partly result from functional cooperation between Mediator and ncRNAs. Indeed, a type of long intergenic ncRNA called activator RNA (aRNA) increases the transcription of neighbouring genes 133 . These aRNAs interact with Mediator, potentially via the MED12 sub unit, and this interaction correlates with transcription activation and gene looping between the aRNA locus and target promoters 134 (FIG. 3) . Importantly, MED12 mutants that are linked to developmental disorders show a reduced ability to form gene loops and associate with aRNAs 134 . As MED12 is part of the CDK8 module, potential ncRNA-MED12 interactions may help to tether the CDK8 module near the promoter. This could facilitate the reversible (on-off) CDK8 moduleMediator interaction at the promoter, thereby regulating Pol II recruitment 18 and/or Pol II elongation 27, 28 . The transcription of enhancer sequences, which appears to be common in mammals, correlates with enhancer-promoter looping and gene activation 1, 127, 135 . In fact, enhancer transcription is considered to be an indicator of enhancer activity (that is, whether the enhancer will activate transcription at a distal promoter) [136] [137] [138] . Although the study of enhancer RNAs (eRNAs) is in its infancy, several groups have shown that Mediator is required for eRNA-dependent enhancer-promoter looping and gene activation, suggesting a functional synergy analogous to aRNAs 139, 140 . Whereas the biogenesis of aRNAs and eRNAs may be distinct 137 , these findings broadly implicate MediatorncRNA interactions in the 3D organization of mammalian genomes. Many important questions remain, such as whether Mediator-ncRNA interactions are specific (that is, if select ncRNA sequences or structures target a specific Mediator subunit) or general (that is, if interactions are RNA sequence-independent), and whether or how ncRNA-Mediator binding might affect Mediator structur e or function.
Interactions between Mediator and the Pol II CTD may also help to stabilize enhancer-promoter gene loops in mammals. Whereas the Pol II CTD binds to both yeast and mammalian Mediator complexes 42, 62, 64 , the length of the CTD has increased from yeast (approximately 26 repeats, depending on species) to humans (52 repeats). This increase in CTD length correlates with an increase in the length of potential DNA looping interactions (that is, increased distance between enhancers and promoters in mammals). Furthermore, it seems that a longer Pol II CTD is required for cell viability in mammals than in yeast 64, 141 . As the Pol II CTD serves as a binding platform for RNA processing factors 79, 80 , a longer CTD could reflect the greater extent and diversity of RNA processing events in mammalian cells (for example, increased 102, 134, 139, 140 . An expanding set of factors influence the formation and stability of these loops 1 , and the formation of such structures correlates with high levels of transcription [125] [126] [127] . As the cyclin-dependent kinase 8 (CDK8) module must dissociate from Mediator to allow RNA polymerase II (Pol II)-Mediator binding 18, 19 , a potential ncRNA-CDK8 module interaction, perhaps via the CDK8 module subunit MED12 (REF. 134 ), may tether the CDK8 module near the pre-initiation complex (PIC). This could facilitate the re-formation of CDK8-Mediator complexes following Pol II promoter escape.
Pericentromeric heterochromatin
Heterochromatin regions near chromosomal centromeres; the primary sites of sister chromatid cohesion.
Telomeric heterochromatin
Heterochromatin regions near telomeres, which are repetitive regions of DNA at the ends of chromosomes.
reliance on splicing, alternative splicing, alternative 3ʹ end processing, and so on). Not mutually exclusive is the possibility that an extended CTD helps to establish longdistanc e enhancer-promoter gene loops that are prevalent in mammalian cells. In fact, it has been demonstrated that Pol II CTD truncations disproportionately reduce enhancer-driven transcription in mammalian cells, whereas transcription directed from promoter-proxima l elements was not markedly affected 142 .
Heterochromatin. In addition to promoting the formation of looped chromatin architectures, studies in model organisms have provided fascinating insights into alternative ways by which Mediator regulates chromatin structure. In the yeast Schizosaccharomyces pombe, Mediator has been linked to pericentromeric heterochromati n formation 143 . These studies suggest that Mediator coordinates Pol II-dependent ncRNA transcription with the RNAi machinery to help to form and maintain hetero chromatin domains [143] [144] [145] . Similarly, Mediator has been implicated in telomeric heterochromati n maintenance in the budding yeast S. cerevisiae. Using genetic screens and cell biology techniques, severa l groups showed that S. cerevisiae Mediator associates with telomeric heterochromatin and may have basic roles in regulating heterochromatin structure at telomeres, as well as in maintaining telomere length [146] [147] [148] [149] . Whereas data linking Mediator to similar functions in mammalian cells have been lacking, it is notable that the D. melanogaster Med26 protein -but not other Mediator subunits -localizes to pericentric heterochromatin and appears to interact with heterochromatin protein 1 (Hp1) 150 . Furthermore, Med26 colocalized with pericentric heterochromatin on D. melanogaster polytene chromosomes, but other Mediator subunits did not 150 ; this may reflect functional antagonism between Hp1 and Mediator, as seen in human cells 151 .
Mediator and signalling cascades Different TFs are activated in response to distinct signalling pathways. For example, the signal transducer and activator of transcription (STAT) family of TFs is activated during infection, and p53 is activated after DNA damage. As different TFs activate transcription, partly by interacting with different Mediator subunits, specific subunits must be able to convert the biological input (for example, developmental cues) to specific transcriptional outcomes (FIG. 4) . In agreement with this, Mediator has been described as the end point of cell signalling pathways because it represents an ultimate, functional target for TFs 152 . Below, we highlight a few pathways that help to illustrate this concept.
TGFβ-SMAD signalling. Signalling through the transforming growth factor-β (TGFβ) receptors ultimately results in the formation of different SMAD TF complexes (for example, SMAD1 and SMAD5 (SMAD1/5) with SMAD4, or SMAD2 and SMAD3 (SMAD2/3) with SMAD4); these complexes form in response to different ligands and control processes such as pluripotency or germ-layer specificity during development. For instance, TGFβ signalling promotes the formation of the SMAD2/3-SMAD4 complex, whereas bone morphogenetic protein (BMP) signalling promotes formation of the SMAD1/5-SMAD4 complex 153 . The transcriptional outcomes of TGFβ signalling in zebrafish are shut down in the absence of MED15, whereas BMP signalling is unaffected 154 . Subsequent experiments confirmed that SMAD2/3 must interact with MED15 to activate its target genes, whereas SMAD1/5 targets a different, unknown Mediator subunit 155 . The MED12 sub unit, perhaps as part of the CDK8 module, also modulates TGFβ signalling by directly binding to TGFβ receptor 2 and inhibitin g its activity 156 . Notably, MED12 regulates CDK8 kinase activity 26, 157 , and CDK8-dependent phosphorylation of SMAD1 or SMAD2/3 fully activates these TFs while also marking them for proteasomal degradation 29, 158 . These observations suggest an intricate regulator y feedback involving Mediator and TGFβ signalling.
WNT-β-catenin signalling. The WNT-β-catenin pathway is crucial for the development of a vast array of tissues, and misregulation of the pathway has been implicated in a variety of cancers 159 . Genetic studies have shown that the CDK8 module subunits MED12 and MED13 are essential for the activation of WNT signalling in metazoans [160] [161] [162] [163] , and binding assays suggest a direct interaction between β-catenin and MED12 (REF. 162 ). In addition, the CDK8 module increases WNT-β-catenin signalling by phosphorylating E2F1. The phosphorylation of E2F1 antagonizes its ability to repress the WNT-β-catenin pathway; it usually represses this pathway by promoting β-catenin degradation 33, 164 . As a consequence, high levels of CDK8 expression can drive colon cancer progression 165 . The CDK8 module therefore facilitates WNT-β-catenin signalling by two mechanisms: mediating the transcription of β-catenin target genes and repressing an opposing pathway through its kinase activity.
RAS-ERK-MAPK signalling.
The RAS-ERK-MAPK pathway helps to regulate cell growth, survival and differentiation via a set of TFs termed the ternary complex factor subfamily that function in part through their interaction with Mediator 166 . Specifically, MED23 is required for RAS-ERK signalling through the ternary complex factor ELK1 in mammals 11 . However, certain cell types are able to signal through the MAPK pathway without MED23. For instance, whereas MAPK signalling is almost completely dependent on MED23 in murine embryonic stem cells, knocking down MED23 in MEFs has only a moderate effect. This is explained by the higher expression of an alternative ternary complex factor, ELK3, in MEFs; because ELK3 does not stimulate transcription through MED23, MED23-knockout MEFs are still able to respond to MAPK signalling 99 . The ELK1-MED23 interaction is necessary for angiogenesis in both MEFs and multipotent mesenchymal stem cells 167, 168 . However, in mesenchymal stem cells, reducing the levels of MED23 leads to adipogenesis rather than angiogenesis 168 . This difference between RAS-ERK signalling in MEFs and mesenchymal stem cells is also Nature Reviews | Molecular Cell Biology Activation of the RAS-ERK-MAPK pathway additionally leads to MED1 phosphorylation, which increases its association with core Mediator and enhances transcription in response to specific TFs 169, 170 .
Concluding remarks
Because of its myriad roles in gene expression, Mediator represents 'fertile ground' on which to cultivate a deeper understanding of transcription regulatory mechanisms. Future work will no doubt expand on the themes discussed here and is likely to reveal completely new structural or functional roles of Mediator. Further studies of Mediator-dependent regulation of chromatin architecture and enhancer-promoter gene loops should yield fundamental insights into the functions of Mediator subunits and define additional roles for them in transcription regulation. New insights may include roles for Mediator in establishing nuclear domains, such as transcription factories 171 , the functional relevance of which is congruent with increasingly sophisticated chromosome conformation capture experiments suggesting that sets of genes can be coordinately regulated via their nuclear colocalization. Interestingly, proteins that bind to RNA or that contain IDRs are capable of forming 'phase domains' in vitro 172, 173 , which provides a means of spatial segregation in the absence of lipid membranes 174 . The formation of such structures requires RNA, and clusters of highly active genes would provide high local concentrations of RNA that could help to promote the formation and stabilization of these domains. Mediator binds to RNA 134 , and its large size and abundance of IDRs 38 suggests that Mediator could help to demarcate transcription factories by facilitating the formation of structural barriers in the nucleus. Although this concept remains to be tested, it is consistent with Mediator's known roles in 3D chromatin organization at sites of active transcription 102, 128 . Recent and future insights regarding Mediator structure and function should provide a framework for the development of methods to manipulate Mediator function for therapeutic purposes. Improvements in the quality of structural data, which will increasingly rely shown. Each pathway is activated by different signals; for instance, WNT-β-catenin signalling is activated during growth and differentiation; p53 is activated during cell stress; Toll-like receptors (TLRs) are activated in response to inflammation and infection, and sterol regulatory element-binding protein 1 (SREBP1) is activated in response to metabolic cues. Each pathway activates a distinct transcription factor (TF) that targets a different Mediator subunit (Mediator subunits that interact with specific TFs are shown in the same colour), which helps to recruit and regulate Mediator activity at select genomic loci. The end result is TF-dependent activation (or repression) of a specific set of genes that are important for the response to the stimulus. Owing to Mediator's role in relaying and integrating these signals directly to the transcription machinery (including the RNA polymerase II (Pol II) enzyme itself), Mediator can be considered an end point of signalling cascades 152 . ER, endoplasmic reticulum; GSK3, glycogen synthase kinase 3; IRF7, interferon regulatory factor 7; MYD88, myeloid differentiation 88; TRAF3, tumour necrosis factor receptor-associated factor 3.
on advances in electron microscopy data collection and image processing, will enhance our mechanistic understanding of the complex and may identify strategies to target Mediator with small molecules. Although the development of small molecules that bind to specific motifs or domains within Mediator would represent only a first step towards molecular therapeutics, such reagents are likely to serve as versatile mechanistic probes to interrogate Mediator function in vitro and in vivo. Finally, advances in genome editing tools, combined with increasingly reliable genomics and informatics approaches, should continue to transform our ability to study Mediator function in cellular and in vivo contexts.
